Sorafenib Completed Phase 2 Trials for Brain and Central Nervous System Tumors Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00621686Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme